What is BridgeBio Pharma's free cash flow?

BridgeBio Pharma (BBIO) reported free cash flow of -$197.35M in Q1 2026.

How has BridgeBio Pharma's free cash flow changed year-over-year?

BridgeBio Pharma's free cash flow increased by 0.9% year-over-year, from -$199.24M to -$197.35M.

What is the long-term trend for BridgeBio Pharma's free cash flow?

Over 3 years (2021 to 2025), BridgeBio Pharma's free cash flow has grown at a -4.4% compound annual growth rate (CAGR), from -$511.18M to -$447.01M.

BridgeBio Pharma BBIO Free cash flow

Free cash flow at other companies

PfizerPFE

$2.18B+23.0%

Revolution Medicines, Inc.RVMD

-$355.7M-79.9%

Ionis PharmaceuticalsIONS

——

BioMarin PharmaceuticalsBMRN

——

ALN

Alnylam PharmaceuticalsALNY

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Calculated from BridgeBio Pharma’s reported figures.

−$197.3Mnet cash from operating−$69.0Kcapital expenditures=-$197.35M

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's free cash flow?: BridgeBio Pharma (BBIO) reported free cash flow of -$197.35M in Q1 2026.
How has BridgeBio Pharma's free cash flow changed year-over-year?: BridgeBio Pharma's free cash flow increased by 0.9% year-over-year, from -$199.24M to -$197.35M.
What is the long-term trend for BridgeBio Pharma's free cash flow?: Over 3 years (2021 to 2025), BridgeBio Pharma's free cash flow has grown at a -4.4% compound annual growth rate (CAGR), from -$511.18M to -$447.01M.